Login / Signup

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.

Massimo GentileEnrica Antonia MartinoAndrea VisentinMarta CosciaGianluigi RedaPaolo SportolettiFrancesca Romana MauroLuca LaurentiMarzia VarettoniRoberta MurruAnnalisa ChiarenzaErnesto VignaFrancesco MendicinoEugenio LuciaSabrina BossioAnna Grazia RecchiaRiccardo MoiaDaniela PietrasantaGiacomo LosetoUgo ConsoliIlaria ScortechiniFrancesca Maria RossiAntonella ZucchettoHamdi Al-JanazrehCandida VitaleGiovanni TripepiD 'Arrigo GraziellaIlaria AngelettiRiccardo BombenAntonino NeriGiovanna CutronaGilberto FronzaFrancesco Di RaimondoGianluca GaidanoAntonio CuneoRobin FoàManlio FerrariniLivio TrentinValter GatteiFortunato Morabito
Published in: Blood cancer journal (2020)
Keyphrases
  • chronic lymphocytic leukemia
  • diffuse large b cell lymphoma
  • acute lymphoblastic leukemia
  • hodgkin lymphoma
  • acute myeloid leukemia
  • multiple myeloma
  • free survival